The efficacy and safety of modified FOLFIRINOX as first‐line chemotherapy for Chinese patients with metastatic pancreatic cancer

Abstract

Modified FOLFIRINOX was well-tolerated and might be a promising option as first-line therapy for Chinese patients with metastatic PC. Trial registration ClinicalTrials.gov, NCT02028806. Registered 7 January 2014, https://clinicaltrials.gov/ct2/show/NCT02028806.